These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 10514023)
1. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Harker LA; Boissel JP; Pilgrim AJ; Gent M Drug Saf; 1999 Oct; 21(4):325-35. PubMed ID: 10514023 [TBL] [Abstract][Full Text] [Related]
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. CAPRIE Steering Committee Lancet; 1996 Nov; 348(9038):1329-39. PubMed ID: 8918275 [TBL] [Abstract][Full Text] [Related]
3. Clopidogrel: a review of its use in the prevention of atherothrombosis. Jarvis B; Simpson K Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738 [TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876 [TBL] [Abstract][Full Text] [Related]
5. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Hankey GJ; Sudlow CL; Dunbabin DW Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426 [TBL] [Abstract][Full Text] [Related]
6. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Creager MA Vasc Med; 1998; 3(3):257-60. PubMed ID: 9892520 [TBL] [Abstract][Full Text] [Related]
7. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ; Lancet; 2004 Jul 24-30; 364(9431):331-7. PubMed ID: 15276392 [TBL] [Abstract][Full Text] [Related]
8. Clopidogrel: new preparation. An alternative to aspirin. Prescrire Int; 1999 Dec; 8(44):163-4. PubMed ID: 11503810 [TBL] [Abstract][Full Text] [Related]
9. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Bhatt DL; Hirsch AT; Ringleb PA; Hacke W; Topol EJ Am Heart J; 2000 Jul; 140(1):67-73. PubMed ID: 10874265 [TBL] [Abstract][Full Text] [Related]
10. The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial. Dippel DW Thromb Res; 1998 Sep; 92(1 Suppl 1):S13-6. PubMed ID: 9781832 [TBL] [Abstract][Full Text] [Related]
11. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Ringleb PA; Bhatt DL; Hirsch AT; Topol EJ; Hacke W; Stroke; 2004 Feb; 35(2):528-32. PubMed ID: 14739421 [TBL] [Abstract][Full Text] [Related]
12. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. Caro JJ; Migliaccio-Walle K Am J Med; 1999 Dec; 107(6):568-72. PubMed ID: 10625025 [TBL] [Abstract][Full Text] [Related]
14. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Hacke W Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184 [TBL] [Abstract][Full Text] [Related]
15. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Sudlow CL; Mason G; Maurice JB; Wedderburn CJ; Hankey GJ Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD001246. PubMed ID: 19821273 [TBL] [Abstract][Full Text] [Related]
16. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations. Logman JF; Heeg BM; Herlitz J; van Hout BA Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780 [TBL] [Abstract][Full Text] [Related]
17. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. Montalescot G Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682 [TBL] [Abstract][Full Text] [Related]
18. Clopidogrel for cerebrovascular prevention. Paciaroni M; Bogousslavsky J Cerebrovasc Dis; 1999; 9(5):253-60. PubMed ID: 10473907 [TBL] [Abstract][Full Text] [Related]
19. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
20. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Brennan DM; Fabry-Ribaudo L; Booth J; Topol EJ; N Engl J Med; 2006 Apr; 354(16):1706-17. PubMed ID: 16531616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]